Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Logo-themed deal toy, incorporating spheres with logos, marking the acquisition of medical advocacy service provider MAP Health. The acquirer was Louisville, Kentucky-based health management software company SentryHealth. (23AKL284)
Crystal deal toy commemorating the acquisition of PharmaSmart, a Rochester, New York-based provider of healthcare screening kiosks. The acquirer was Canadian private equity firm CPS Capital. (23AKL282)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Crystal commemorative marking a licensing and commercialization agreement between Corbus Pharmaceuticals and CSPC Pharmaceutical Group. The agreement centers on a potential treatment for tumors associated with lung, breast, and prostate cancers. (23AZH089)
Ark-themed crystal deal toy marking the acquisition by CVS of Signify Health. The home healthcare services company is headquartered in Dallas. (23AKL198)
Crystal deal tombstone marking a follow-on offering by life sciences company Intelligent Bio Solutions The design incorporates the firm’s drug screening cartridge. (23AJH030)
Crystal financial tombstone marking a private placement by Midatech Pharma. The drug delivery technology firm is based in the UK. (23AJH028)
Crystal financial tombstone celebrating Series A funding for Lokavant. Based in New York, Lokavant provides a centralized data repository for clinical drug trials. (23AKL083)
